HC Wainwright Reaffirms “Buy” Rating for Amyris, Inc. (AMRS)
Amyris, Inc. (NASDAQ:AMRS)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Wednesday. They presently have a $15.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 324.93% from the company’s previous close.
Other equities research analysts have also issued research reports about the company. Zacks Investment Research raised Amyris from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research report on Wednesday, October 4th. Cowen and Company set a $4.00 price target on Amyris and gave the stock a “hold” rating in a research report on Thursday, August 17th. Finally, ValuEngine raised Amyris from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Amyris currently has a consensus rating of “Hold” and an average price target of $20.69.
Amyris (NASDAQ AMRS) traded up $0.44 during midday trading on Wednesday, hitting $3.53. The stock had a trading volume of 731,104 shares, compared to its average volume of 260,584. The company has a current ratio of 0.65, a quick ratio of 0.56 and a debt-to-equity ratio of -0.76. Amyris has a 52 week low of $1.86 and a 52 week high of $14.85.
Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.04). The firm had revenue of $24.20 million during the quarter, compared to the consensus estimate of $36.30 million. Amyris’s revenue for the quarter was down 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.07) earnings per share. research analysts anticipate that Amyris will post -3.32 earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in AMRS. Bank of New York Mellon Corp raised its position in Amyris by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 4,603 shares during the last quarter. Carl Domino Inc acquired a new stake in Amyris in the 3rd quarter valued at approximately $182,000. KBC Group NV raised its position in Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 41,834 shares during the last quarter. Finally, Tanaka Capital Management Inc. raised its position in Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 221,295 shares during the last quarter. 19.99% of the stock is currently owned by institutional investors and hedge funds.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.